Cargando…

Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka

Sri Lanka is a developing country with a population of 21 million. Nation Cancer Institute (NCI) is the largest tertiary cancer centre with universal health coverage. Absence of hematopoietic stem cell transplant (HSCT) was a major deficiency as most patients cannot afford transplant abroad. In 2013...

Descripción completa

Detalles Bibliográficos
Autores principales: Abeysinghe, P, Morawaka, L, Gunasekara, S, Suresh, S, Jayathilake, PWDCC, Udara, PHSP, Siriwardena, PPR, Milliken, S, Moore, J, Ma, DDF
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia-Pacific Blood and Marrow Transplantation Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427228/
https://www.ncbi.nlm.nih.gov/pubmed/37588103
http://dx.doi.org/10.31547/bct-2019-007
_version_ 1785090189732872192
author Abeysinghe, P
Morawaka, L
Gunasekara, S
Suresh, S
Jayathilake, PWDCC
Udara, PHSP
Siriwardena, PPR
Milliken, S
Moore, J
Ma, DDF
author_facet Abeysinghe, P
Morawaka, L
Gunasekara, S
Suresh, S
Jayathilake, PWDCC
Udara, PHSP
Siriwardena, PPR
Milliken, S
Moore, J
Ma, DDF
author_sort Abeysinghe, P
collection PubMed
description Sri Lanka is a developing country with a population of 21 million. Nation Cancer Institute (NCI) is the largest tertiary cancer centre with universal health coverage. Absence of hematopoietic stem cell transplant (HSCT) was a major deficiency as most patients cannot afford transplant abroad. In 2013-14, NCI decided to establish the first National HSCT center in collaboration with St. Vincent's Hospital Sydney. Eventually, the first Autologous HSCT was established at NCI in December 2016. Patients with multiple myeloma (MM) in very good partial remission or better remission, and patients with relapsed Non-Hodgkin's lymphoma (NHL) and Hodgkin lymphoma (HL), who were less than 65 years with good performance status were selected. Stem cells were mobilized with cyclophosphamide and G-CSF and the products were cryopreserved. Melphalan was the conditioning regime for MM while BEAM was used for HL and NHL. Twenty autologous transplants were performed in the first year. Mean age was 47 years (range: 17-62) and male to female ratio was 3: 2. There were 17 MM and one each of NHL, HL and POEMS syndrome patients. Median CD34+ stem cells collected was 12.72×10(6)/kg (range: 3-31) and median infused cell dose was 4.07×10(6)/kg (range: 2-7.4). Median engraftment day was 13 (range: 11-19) and median hospitalization was 16 days (range: 14-20). All developed febrile neutropenia and GradeⅢ thrombocytopenia. Zero transplant-related mortality was observed with acceptable morbidity. At the median follow-up of 47 weeks, the overall survival was 100% with all the patients still in remission.
format Online
Article
Text
id pubmed-10427228
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Asia-Pacific Blood and Marrow Transplantation Group
record_format MEDLINE/PubMed
spelling pubmed-104272282023-08-16 Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka Abeysinghe, P Morawaka, L Gunasekara, S Suresh, S Jayathilake, PWDCC Udara, PHSP Siriwardena, PPR Milliken, S Moore, J Ma, DDF Blood Cell Ther Survey Report Sri Lanka is a developing country with a population of 21 million. Nation Cancer Institute (NCI) is the largest tertiary cancer centre with universal health coverage. Absence of hematopoietic stem cell transplant (HSCT) was a major deficiency as most patients cannot afford transplant abroad. In 2013-14, NCI decided to establish the first National HSCT center in collaboration with St. Vincent's Hospital Sydney. Eventually, the first Autologous HSCT was established at NCI in December 2016. Patients with multiple myeloma (MM) in very good partial remission or better remission, and patients with relapsed Non-Hodgkin's lymphoma (NHL) and Hodgkin lymphoma (HL), who were less than 65 years with good performance status were selected. Stem cells were mobilized with cyclophosphamide and G-CSF and the products were cryopreserved. Melphalan was the conditioning regime for MM while BEAM was used for HL and NHL. Twenty autologous transplants were performed in the first year. Mean age was 47 years (range: 17-62) and male to female ratio was 3: 2. There were 17 MM and one each of NHL, HL and POEMS syndrome patients. Median CD34+ stem cells collected was 12.72×10(6)/kg (range: 3-31) and median infused cell dose was 4.07×10(6)/kg (range: 2-7.4). Median engraftment day was 13 (range: 11-19) and median hospitalization was 16 days (range: 14-20). All developed febrile neutropenia and GradeⅢ thrombocytopenia. Zero transplant-related mortality was observed with acceptable morbidity. At the median follow-up of 47 weeks, the overall survival was 100% with all the patients still in remission. Asia-Pacific Blood and Marrow Transplantation Group 2019-11-25 /pmc/articles/PMC10427228/ /pubmed/37588103 http://dx.doi.org/10.31547/bct-2019-007 Text en Copyright Ⓒ2019 Asia-Pacific Blood and Marrow Transplantation Group (APBMT). https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Survey Report
Abeysinghe, P
Morawaka, L
Gunasekara, S
Suresh, S
Jayathilake, PWDCC
Udara, PHSP
Siriwardena, PPR
Milliken, S
Moore, J
Ma, DDF
Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka
title Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka
title_full Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka
title_fullStr Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka
title_full_unstemmed Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka
title_short Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka
title_sort country report: the report of transplant activity and outcome during the first 12 months at the first national hematopoietic stem cell transplant center in sri lanka
topic Survey Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427228/
https://www.ncbi.nlm.nih.gov/pubmed/37588103
http://dx.doi.org/10.31547/bct-2019-007
work_keys_str_mv AT abeysinghep countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka
AT morawakal countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka
AT gunasekaras countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka
AT sureshs countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka
AT jayathilakepwdcc countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka
AT udaraphsp countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka
AT siriwardenappr countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka
AT millikens countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka
AT moorej countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka
AT maddf countryreportthereportoftransplantactivityandoutcomeduringthefirst12monthsatthefirstnationalhematopoieticstemcelltransplantcenterinsrilanka